
Our people make us who we are
At UroGen, we're passionate about making a difference for patients with urothelial and specialty cancers—and we know true progress can only be made when diverse minds come together for this common goal.
Learn more about UroGen >
Our people make us who we are
At UroGen, we're passionate about making a difference for patients with urothelial and specialty cancers—and we know true progress can only be made when diverse minds come together for this common goal.
Learn more about UroGen>An industry-leading uro-oncology pipeline
Our investigational product candidates put us on the cutting edge of advancing treatments for urothelial and specialty cancers, including non-muscle invasive bladder cancer.
Explore our pipeline >

An industry-leading uro-oncology pipeline
Our investigational product candidates put us on the cutting edge of advancing treatments for urothelial and specialty cancers, including non-muscle invasive bladder cancer.
Explore our pipeline >
Our trailblazing therapies
JELMYTO® (mitomycin) for pyelocalyceal solution is the first FDA-approved treatment using our novel RTGel® technology. JELMYTO is the first and only treatment of its kind and received breakthrough approval in April 2020.
See our products and solutions >
Our trailblazing therapies
JELMYTO® (mitomycin) for pyelocalyceal solution is the first FDA-approved treatment using our novel RTGel® technology. JELMYTO is the first and only treatment of its kind and received breakthrough approval in April 2020.
See our products and solutions >